QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 illumina-releases-its-novel-5-base-solution-for-multiomic-analysis-enabling-simultaneous-detection-of-genomic-variants-and-dna-methylation-from-a-single-sample

Illumina, Inc. (NASDAQ:ILMN) today announced the release of its novel 5-base solution, enabling researchers to pursue broader b...

 cathie-wood-warns-wall-street-is-missing-ais-biggest-opportunity-in-healthcare-calling-it-sleeper-investment-poised-for-massive-returns

Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its p...

 evercore-isi-group-maintains-outperform-on-illumina-lowers-price-target-to-132

Evercore ISI Group analyst Vijay Kumar maintains Illumina (NASDAQ:ILMN) with a Outperform and lowers the price target from $...

 illumina-launches-new-business-bioinsight-to-advance-multiomic-data-interpretation-for-pharma-and-research-partners

New business focuses on developing data assets, software, and AI to fuel life science breakthroughsExpands pharma access to lar...

 trump-administration-review-targets-medical-supply-chain-vulnerabilities

The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—includ...

 illumina-partners-with-multiple-global-pharma-companies-to-develop-companion-diagnostics-enabled-on-the-trusight-oncology-comprehensive-genomic-profiling-test

Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarkerSAN DIEGO, Sept. 23, 2...

 element-biosciences-sues-illumina-alleging-anticompetitive-behavior-patent-infringement--genomeweb

https://www.genomeweb.com/sequencing/element-biosciences-sues-illumina-alleging-anticompetitive-behavior-patent-infringement

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

Core News & Articles

Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene sile...

 illumina-launches-protein-prep-assay-targeting-9500-human-proteins-to-accelerate-disease-research-following-early-access-success

Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel d...

 icahn-hedge-funds-q2-moves-centuri-stake-soars-jetblue-held-2-positions-exited

Carl Icahn's 13F shows concentrated equity book, with top 10 holdings making up 98.76%. Notable changes in non-house names ...

 nice-stock-stops-being-nice-has-a-bearish-breakdown

NICE Ltd. has ended a 15-year trend with a bearish breakdown, signaling extended downside risk. Here's what the Adhishthana...

 illumina-settles-with-doj-veterans-to-end-whistleblower-lawsuit

Illumina will pay $9.8 million to settle allegations it sold genomic systems with cybersecurity flaws to U.S. agencies. A whist...

 morgan-stanley-maintains-equal-weight-on-illumina-raises-price-target-to-105

Morgan Stanley analyst Tejas Savant maintains Illumina (NASDAQ:ILMN) with a Equal-Weight and raises the price target from $1...

 cathie-woods-ark-invest-loads-up-on-coinbase-roku-illumina-and-bitmine-immersion

Cathie Wood-led Ark Invest made significant trades in COIN, ROKU, ILMN, and BMNR. They also bought PD and SOFI, sold KTOS and R...

 rbc-capital-maintains-outperform-on-illumina-raises-price-target-to-126

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:ILMN) with a Outperform and raises the price target from $118 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION